Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128514 | 0.82 | TSHR (0.42) | PPARDTSHRTP53TDP1PGK1 | |
| SCHEMBL25559188 | 0.78 | PPARD (0.35) | PPARDTSHRTP53TDP1ALDH1A1 | |
| SCHEMBL10128274 | 0.77 | TSHR (0.42) | PPARDTSHRTP53TDP1ACHE | |
| SCHEMBL9115357 | 0.77 | TSHR (0.46) | PPARDTSHRTP53TDP1ACHE | |
| SCHEMBL3502263 | 0.76 | TSHR (0.40) | PPARDTSHRTP53TDP1ACHE | |
| SCHEMBL11737002 | 0.75 | TSHR (0.43) | PPARDTSHRTP53TDP1ACHE | |
| SCHEMBL11693393 | 0.74 | TSHR (0.48) | PPARDTSHRTP53TDP1ACHE | |
| SCHEMBL10128561 | 0.73 | PGK1 (0.63) | TSHRTDP1PGK1PGK2LPAR1 | |
| SCHEMBL4550022 | 0.72 | PPARD (0.38) | PPARDTSHRTP53TDP1CA12 | |
| SCHEMBL10154906 | 0.72 | TSHR (0.33) | PPARDTSHRTP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057173-B1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022482-A1 | aSMase inhibitors | SMPD1, SMPD3, SMPD2 | PPARD 3969/4885TSHR 2541/4885TP53 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.